INTRODUCTION Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide drugs and certain low molecular weight proteins (insulin) and cytokines.
New York, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Microbial Contract Biomanufacturing Market, 2020-2030" - https://www.reportlinker.com/p05987914/?utm_source=GNW
Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (with potential application areas in cell and gene therapies, and DNA vaccines), has led to a substantial increase in demand for microbial system-based production. Furthermore, evolutionary advances in manufacturing technologies have resulted in a renewed interest from drug developers in using microbial platforms for the production of complex biologics.
Given the inherent complexities in the development and production of biologics, drug developers have demonstrated the preference to outsource parts of their microbial manufacturing operations, as well. In fact, there has been a rise in the outsourcing activity in relation to microbial fermentation since 2017. Presently, the microbial contract biomanufacturing market features a mix of small, mid-sized and large players, offering end-to-end solutions, ranging from early stage process development to clinical and commercial scale manufacturing and regulatory filing. Despite this being a fairly well-established domain, more than 25 new contract microbial fermentation companies have been established over the last decade. Therefore, in order to remain competitive, CMOs / CDMOs have begun active in acquiring cutting-edge fermentation technologies and investing in the development of the necessary capacity to support the growing demand for novel biologics. It is also worth highlighting that the COVID-19 pandemic is also likely to create significant business opportunities for microbial CMOs as innovator companies are expected to seek support in manufacturing of potential vaccines and other therapeutic modalities. In the long term, we are led to believe that the contract services market catering to this segment of the biopharma industry is anticipated to witness substantial growth in the coming years.
SCOPE OF THE REPORT
The “Microbial Contract Biomanufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:
- A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any).
- A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).
- An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography. Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity.
- An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
- A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.
- A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
- Elaborate profiles of key players that offer contract biomanufacturing services using microbial expression systems across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.
- A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- An insightful discussion on the impact of COVID-19 outbreak on the overall microbial contract biomanufacturing market, and the key initiatives undertaken by CMOs to combat the challenges posed due to ongoing situation.
One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbial contract biomanufacturing market. Based on multiple parameters, such as projected growth of the overall microbial biomanufacturing market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of biologic (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] scale of operation (preclinical / clinical and commercial) [D] end user (small, mid-sized and large / very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
- Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
- Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)
- Max Rossetto (General Manager, Business Development, Luina Bio)
- Rob van Dijk (Business Development Manager, WACKER Biotech)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views
While the focus has been on forecasting the market over the coming decade, the report also provides our independent view on various emerging trends in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market, gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
- Who are the leading CMOs with expertise in production of microbial biologics?
- What are the preferred microbial expression systems used in biologic development and manufacturing?
- What are the key microbial fermentation technology platforms?
- Who could be the potential partners for the microbial CMOs?
- What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
- What type of expansion initiatives are being carried out by CMOs in this domain?
- What initiatives are being undertaken by big pharma players in this domain?
- What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?
- What are the key trends within the microbial contract biomanufacturing market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbial contract biomanufacturing market and its likely evolution in the short-mid-term and long term.
Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various microbial expression systems used for the development of different types of biologics. Further, it features a brief overview of contract manufacturing and includes a detailed discussion on the need for outsourcing within the microbial biopharmaceutical industry. In this chapter, we have presented a list of commonly outsourced microbial biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently faced by players engaged in the market.
Chapter 4 provides an overview of the current microbial contract biomanufacturing landscape. It includes information on close to 115 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, scale of operation, geographical location of the headquarters, number and location of production facilities, type of biologics manufactured, type of microbial expression system used, type of fermenter used, type of services offered, and regulatory accreditations / certifications received (if any).
Chapter 5 provides a detailed 3-D company competitiveness analysis of microbial contract manufacturers based in North America, Europe, Asia Pacific and Middle East, that we came across during our research. The analysis compares companies within each geography on the basis of company experience (considering the experience of contract manufacturer) and company expertise (which takes into account the count of service portfolio, number of biologics manufactured, number of expression system used and scale of operation).
Chapter 6 features detailed profiles of key industry players that offer contract biomanufacturing services using microbial expression systems across different geographies such as, North America, Europe and Asia Pacific and Middle East, at all scales of operation. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, and an informed future outlook.
Chapter 7 features an elaborate analysis of the various partnerships that have been inked amongst players in this domain, in the time period 2016-2020. It provides a brief description on the various types of partnership model (which include manufacturing agreements, product development agreements, process development agreement, service alliances, and others) that have been adopted by stakeholders in this domain. Further, it features the detailed analysis based on the year of agreement, partnership model, scale of operation, type of biologic, focus area of the deal, therapeutic area and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. In addition, it features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, along with the geographical distribution of this activity.
Chapter 8 presents detailed analysis on the various expansion initiatives undertaken by contract biomanufacturers using microbial expression systems, in order to augment their capabilities, over the period 2016-2020. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain.
Chapter 9 provides a list of microbial fermentation technology platforms that are either available in the market. In addition, it features a list of emerging microbial fermentation technologies.
Chapter 10 features a proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.
Chapter 12 provides a detailed analysis of microbial based biopharmaceuticals manufacturing related initiatives of the big pharma players (shortlisted from the top companies of 2019 by revenues), featuring trends across various parameters, such as number of initiatives, year of initiative and type of initiatives.
Chapter 13 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.
Chapter 14 presents a detailed market forecast analysis, highlighting the likely growth of the microbial contract biomanufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] distribution by type of biologics (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] type by scale of operation (preclinical / clinical and commercial) [D] end user (small, mid-sized and large / very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America).
Chapter 15 highlights the effect of coronavirus outbreak on the global microbial contract biomanufacturing industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for drug developers and CMOs to combat the challenges posed due to ongoing situation. In addition, it includes a brief section on strategies and action plans that biopharma companies are likely to adopt in order to prepare for supply chain disruptions in future.
Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of microbial contract biomanufacturing market, under a SWOT framework.
Chapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbial contract biomanufacturing market, based on the research and analysis described in the previous chapters.
Chapter 18 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), Andrea Conforto (Sales and Marketing, Bioservices Director, Olon), Max Rossetto (General Manager, Business Development, Luina Bio) and Rob van Dijk (Business Development Manager, WACKER Biotech).
Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.
Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.
Read the full report: https://www.reportlinker.com/p05987914/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001